Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Silo Pharma, Inc. - Common Stock (NQ:SILO)

0.2844 -0.0056 (-1.93%)
Streaming Delayed Price Updated: 2:06 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Silo Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Silo Pharma Announces Closing of $2 Million Public Offering
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Prices $2 Million Public Offering of Common Stock and Warrants
Via Investor Brand Network
InvestorkNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Engages Veloxity Labs for IND-Enabling Study of PTSD Drug SPC-15
Via Investor Brand Network
News headline image
Silo Pharma Announces Pricing of $2 Million Public Offering
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances PTSD Treatment with FDA-Requested Safety Study for SPC-15
Via Investor Brand Network
News headline image
Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories
Clear Regulatory Path to Clinical Trials for Intranasal PTSD Therapy Targeting Multi-Billion-Dollar Market 
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Reports Positive Preclinical Data for SP-26 Ketamine Implant
Via Investor Brand Network
News headline image
Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent Application for Alzheimer’s Drug SPC-14
Via Investor Brand Network
Topics Intellectual Property
News headline image
Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer’s Drug
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Begins Final Preclinical Study for PTSD Treatment SPC-15
Via Investor Brand Network
News headline image
Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Secures USPTO Patent for PTSD Treatment SPC-15
Via Investor Brand Network
Topics Intellectual Property
News headline image
Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Provisional Patent for SPC-15 Dual-Action Treatment
Via Investor Brand Network
Topics Intellectual Property
News headline image
Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Reports Positive Early Data on SP-26 Ketamine Implant Study
Via Investor Brand Network
Topics Animal Testing
News headline image
Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Bolsters Intellectual Property with New Patent Filing for PTSD Treatment
Via Investor Brand Network
Topics Intellectual Property
News headline image
Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Strengthens Patent Portfolio with Approval for PTSD Treatment SPC-15
Via Investor Brand Network
Topics Intellectual Property
News headline image
Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances Ketamine Implant Development with Pharmacokinetic Study
Via Investor Brand Network
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Partners with Kymanox to Advance Ketamine Implant Therapeutic for Chronic Pain
Via Investor Brand Network
News headline image
Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Promising Preclinical Results for SPC-15 in Treating Severe Psychiatric Disorders
Via Investor Brand Network
News headline image
Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders
From Silo Pharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.